drugset / Trial / NCT03954158

Study to Assess Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Participants Aged ≥2 Years With Mild to Moderate Atopic Dermatitis

NCT03954158

Phase 2 Completed 81 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 2b, multi-center, randomized, double-blind, vehicle-controlled, intraparticipant study to evaluate efficacy and safety of two regimens of crisaborole ointment 2% in Japanese pediatric and adult participants (cohort 1: 12 years and older, cohort 2: 2 to under 12 years old) with mild to moderate Atopic Dermatitis (AD).

Timeline

Start
2019-06-15
Primary completion
2019-12-16
Completion
2019-12-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Crisaborole Small molecule 2 %

Indications